Eyenuk Inc.’s AI-based diabetic retinopathy screening software EyeArt™ tested with portable smartphone-based imaging device in new study indicating potential for highly sensitive yet cost-effective mass retinal screening

Nature Eye Article

A new study published in the international ‘Eye’ journal (Springer Nature) demonstrated very high sensitivity for detecting any diabetic retinopathy (95.8%) and sight-threatening diabetic retinopathy (99.1%) using EyeArt™ automated screening software with Remidio Fundus on Phone system. LOS ANGELES, CA, March 12, 2018 — Eyenuk, Inc., a leading developer of advanced clinically supported artificial intelligence […]

Continue Reading »

Eyenuk, Inc. Receives Health Canada Approval for EyeArt™, an AI-enabled Cloud-based Automated Diabetic Retinopathy Screening Software


Eyenuk’s quality management system has been registered under the Medical Device Single Audit Program (“MDSAP”) as conforming to the requirements of ISO 13485:2003, after successfully completing an audit for the relevant quality management system requirements of the U.S. Food and Drug Administration and Health Canada. LOS ANGELES, CA, March 8, 2018 — Eyenuk, Inc., a […]

Continue Reading »